CLINICAL BENEFIT OF ADALIMUMAB DOSE ADJUSTMENT FOR PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN’S DISEASE IN EXTEND
Jean-Frederic Colombel 1
Paul Rutgeerts 2
William Sandborn 3
Douglas C. Wolf 4
Walter Reinisch 5
Gert Van Assche 2
Samantha Eichner 6
Joel Petersson 7
Anne M. Robinson
Roopal B Thakkar
1 Icahn School Of Medicine At Mount Sinai, New York, United States
2 University Of Leuven, Leuven, Belgium
3 Ucsd, La Jolla, United States
4 Atlanta Gastroenterology Associates, Atlanta, United States
5 Mcmaster University, Hamilton, Canada
6 Abbvie Inc, North Chicago, United States
7 Abbvie Inc, North
Conference
UEG Week 2014
Citation
United European Gastroenterology Journal; 2014: 2 (Supplement 1)
Login to access library content
Do you need help setting up your myUEG account?
Contact us at office@ueg.eu